Fielder Capital Group’s AbbVie ABBV Stock Holding History

Fielder Capital Group’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$541K	Buy	2,489 +14	+0.6%	+$3.11K	0.12%	119
2025 Q4	$566K	Sell	2,475 -16	-0.6%	-$3.65K	0.12%	106
2025 Q3	$577K	Sell	2,491 -25	-1%	-$5.09K	0.13%	99
2025 Q2	$467K	Buy	2,516 +102	+4%	+$19K	0.12%	109
2025 Q1	$506K	Buy	2,414 +32	+1%	+$6.22K	0.15%	92
2024 Q4	$423K	Buy	2,382 +113	+5%	+$20.8K	0.13%	112
2024 Q3	$448K	Buy	2,269 +14	+0.6%	+$2.61K	0.15%	98
2024 Q2	$387K	Buy	2,255 +77	+4%	+$12.8K	0.15%	95
2024 Q1	$397K	Buy	2,178 +12	+0.6%	+$2.07K	0.18%	86
2023 Q4	$336K	Buy	+2,166	New	+$316K	0.2%	86

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fielder Capital Group's ABBV Position: Q1 2026 in Review

Fielder Capital Group increased its AbbVie (ABBV) stake by 0.57% in Q1 2026, buying an estimated $3.11K and bringing the position to 2,489 shares worth $541K. The position accounts for 0.12% of the portfolio, ranked #119.

Fielder Capital Group first reported a position in ABBV in Q4 2023 and has held it in 10 quarters since. The position peaked at $577K in Q3 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Fielder Capital Group held 2,489 shares of AbbVie worth $541K as of Q1 2026.
Fielder Capital Group bought 14 AbbVie shares in Q1 2026, an estimated $3.11K.
AbbVie made up 0.12% of Fielder Capital Group's portfolio in Q1 2026, its #119 holding.
Fielder Capital Group first reported a position in AbbVie in Q4 2023 and has held it in 10 quarters since.
Fielder Capital Group's AbbVie position peaked at $577K in Q3 2025.
4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Fielder Capital Group's 13F filing for Q1 2026, filed 12 May 2026.